fig7

RNA antisense and silencing strategies using synthetic drugs for rare muscular and neuromuscular diseases

Figure 7. Therapeutic exon skipping. An ASO targeting and blocking an intronic splice acceptor or donor site or an exonic splice enhancer site enforces exon skipping. In the case of the picture, the ASO targets and binds to the acceptor site of intron N+1, resulting in the skipping of ExonN+2. The exons N+1 and N+3 must be in frame to ensure the expression of a protein devoid of only exon N+2, which might still be fully or partially functional.

Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Follow Us

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/